FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
SESVanderHave, the global market leader in sugarbeet seed, is investing over 10 million euro in a brand new high-tech research center on the site of the nearby Feed Food Health-site. Through the construction of this center SESVanderHave is raising its R & D capacity to a higher level. The research center will be more than 20,000 m², and up to fifty people will work there. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, todayannounces that the 50th retina center has been activated to evaluate patients in the US ORBIT Phase IV study with JETREA®. ORBIT (Ocriplasmin Research to Better Inform Treatment) is an observational study designed to generate further data on the real-world use of JETREA® in the US. Patient enrollment is open and underway at all activated sites. read more
Galapagos NV (Euronext: GLPG) announces that Guillaume Jetten will resign as Chief Financial Officer of Galapagos, effective 1 May 2014. Laure Verhaegen, Vice President Finance, will act as interim CFO until a replacement has been recruited. read more
Galapagos NV (Euronext: GLPG) received notice that Baker Brothers Life Sciences L.P., 667 L.P. and 14159 L.P. currently collectively hold 4.99% of outstanding Galapagos shares. read more
Ablynx [Euronext Brussels: ABLX] today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 85,098 common shares have been issued by the Company in exchange for €451,598.59 as the result of the exercise of warrants by some employees and consultants of the Company. read more
Ablynx [Euronext Brussels: ABLX] today announced that it has started dose administration in healthy volunteers in a Phase I clinical trial as part of the evaluation of a subcutaneous formulation of its anti-IL-6R Nanobody®, ALX-0061, for the treatment of inflammatory diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). read more
Op zaterdag 26 april 2014 verzamelen meer dan 1.500 particuliere beleggers in Antwerpen voor het jaarlijks congres van de Vlaamse beleggersfederatie VFB. Dit jaar gaat speciale aandacht naar de sector van de biotechnologie en levenswetenschappen. Enkele toonaangevende beursgenoteerde bedrijven uit onze sector zullen zich die dag voorstellen aan het beleggerspubliek. Ook Genticel, het Franse biotechbedrijf met tal van Belgische links, dat onlangs naar de beurs ging in Parijs en Brussel, zal van de partij zijn. read more
MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that it has signed an agreement with Galaxy Health Network, a Preferred Provider Organization (PPO). The agreement provides patients nationwide with greater access to MDxHealth's ConfirmMDx® for Prostate Cancer test. This agreement extends ConfirmMDx for Prostate Cancer testing to approximately 147 million covered lives throughout the U.S. read more
IBBL (Integrated BioBank of Luxembourg) announces the results of its biorepository Proficiency Testing (PT) Programme, endorsed by ISBER (International Society for Biological and Environmental Repositories). This year, for the first time, the biobank was able to offer a PT testing scheme for DNA extraction from whole blood, thanks to the PAXgene® Blood DNA Tube CE, from PreAnalytiX GmbH, a joint venture between leading medical technology company BD (Becton, Dickinson and Company) and QIAGEN, a global leader in molecular sample and assay technologies. read more
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that JETREA® (ocriplasmin) has been approved in Malaysia for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. The approval, the first in Asia, was gained following a Priority Review that was granted in September 2013. read more